- is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.
Detailed information on Ipsen S.A. required for business and competitor intelligence needs
A study of the major internal and external factors affecting Ipsen S.A. in the form of a SWOT analysis
An in-depth view of the business model of Ipsen S.A. including a breakdown and examination of key business segments
Intelligence on Ipsen S.A.’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
News about Ipsen S.A., such as business expansion, restructuring, and contract wins
Large number of easy-to-grasp charts and graphs that present important data and key trends
Ipsen (or ‘the group’) is a global biopharmaceutical group with products in targeted therapeutic areas such as oncology, endocrinology, neurology, and primary care. The group primarily operates in Europe and North America. It is headquartered in Boulogne-Billancourt, France, and employed 4,835 people as of December 31, 2012. The group recorded revenues of E1,277.4 million ($1,642.5 million*) during the financial year ended December 2012 (FY2012), an increase of 5.6% over FY2011. The operating profit of the group was E114.8 million ($147.6 million*) in FY2012, an increase of 58.1% over FY2011. The net loss was E29.5 million ($37.9 million*) in FY2012, as compared to a net profit of E0.4 million ($0.5 million*) in FY2011. *Calculated using a constant conversion rate of E1 = $1.2858 for the year ended December 31, 2012.
Reasons to Purchase:
Gain understanding of Ipsen S.A. and the factors that influence its strategies
Track strategic initiatives of the company and latest corporate news and actions
Assess Ipsen S.A. as a prospective partner, vendor or supplier
Support sales activities by understanding your customers' businesses better
Stay up to date on Ipsen S.A.’s business structure, strategy and prospects